News
Axpaxli
Successful Phase 3 study results for Ocular's Axpaxli wet AMD drug
Ocular Therpeutix announced successful results of their experimental drug Axpaxli in treating wet age-related macular degeneration.
EyePoint
New AMD drug completes Phase 2 trial
EyePoint Pharmaceuticals announced the completion of the Phase 2 trial of their new experimental drug, vorolanib, for the treatment of wet age-related macular degeneration.
diabetic macular edema
Regeneron receives FDA approval for EYLEA HD
The Food and Drug Administraton (FDA) gave approval after two active-controlled, double-masked pivotal trials, which compared EYLEA HD to EYLEA over a 48 week period.